Clinical Trial Update: Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety and immunogenicity of combined PPV23 and IIV4 immunization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia Pneumococcal

Drugs mentioned

• IIV4 (inactivated influenza vaccine for quadrivalent formulation)
• PPV23 (pneumococcal polysaccharide vaccine)

Snippet

Sponsor: China National Biotec Group Company Limited | Conditions: Influenza, Human, Pneumonia, Pneumococcal | Phase 4 | Status: COMPLETED